Home>Topics>Authors>Damien Conover

Damien Conover

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. The Friday Five

    Video Reports

    Thu, 8 May 2014

    includes things like Claritin, Coppertone, and Dr. Scholl's foot insoles--and sending them over to Bayer. Damien Conover , our health-care analyst, thinks this is a good deal for both sides. Merck is getting a good price for these

    Damien Conover found at 2:54

    Claritin, Coppertone, and Dr. Scholl's foot insoles--and sending them over to Bayer. Damien Conover , our health-care analyst, thinks this is a good deal for both sides. Merck is getting a good price for these businesses right
  2. The Friday Five

    Video Reports

    Thu, 1 May 2014

    AstraZeneca possibly having a deal. What's our take on this? Glaser: This deal likely makes a lot more sense. Damien Conover , our health-care analyst, sees [TICKER:AZN] AstraZeneca as having somewhat of the bloated cost structure

    Damien Conover found at 2:35

    take on this? Glaser: This deal likely makes a lot more sense. Damien Conover , our health-care analyst, sees [TICKER:AZN] AstraZeneca as having somewhat of the bloated cost structure. Pfizer would be able to come in and get
  3. Pfizer-Astra Deal Will Get Done

    Video Reports

    Mon, 28 Apr 2014

    Cost-cutting, tax opportunities, and oncology synergies are motivating factors for Pfizer, and the firms will likely agree to merge, says Morningstar's Damien Conover .

  4. Johnson & Johnson's Pharma Group Leading the Way

    Video Reports

    Tue, 15 Apr 2014

    The firm's consumer and medical-device group are lagging, but strong results from the pharmaceuticals side should drive earnings throughout this year and into 2015, says Morningstar's Damien Conover .

  5. The Sector Is Fairly Valued, but These Stocks Are Not

    Video Reports

    Thu, 10 Apr 2014

    investments, the market, economic indicators, and more. Join us every day for fresh insights from our analyst team. Damien Conover : Today we're talking about health care, and when we think about health care, there are a lot of different industries

    Damien Conover found at 0:03

    more. Join us every day for fresh insights from our analyst team. Damien Conover : Today we're talking about health care, and when we think about health care, there are a lot of different industries within health
  6. Affordable Care Act: Good or Bad Medicine for the Health-Care Sector?

    Headlines

    Sat, 22 Feb 2014

    I talked with Morningstar health-care analysts Damien Conover and Vishnu Lekraj. Our discussion took place Dec ..... our buck. Will the new law change that dynamic? Damien Conover : The United States spends a much higher percentage

  7. Prescribe to Pharma for Emerging-Markets Growth

    Video Reports

    Thu, 12 Dec 2013

    here with me today is Morningstar analyst, Damien Conover . Hello, Damien. Damien Conover : Hi, Emma. Thanks for having me. Wall ..... those yields. Wall: Thank you very much, Damien Conover : Thanks for having me, Emma. Wall: This

    Damien Conover found at 0:06, 2:33

    Wall:  I'm Emma Wall. And here with me today is Morningstar analyst, Damien Conover . Hello, Damien. Damien Conover :  Hi, Emma. Thanks for having me. Wall:  Today, we are going to talk about emerging-markets revenues, but through developed-markets-listed stocks because emerging
    where it's hard to get those yields. Wall:  Thank you very much, Damien Conover :  Thanks for having me, Emma. Wall:  This is Emma Wall for Morningstar. Thank you for watching.
  8. The Friday Five

    Video Reports

    Fri, 3 May 2013

    the line that they'll be able to replace those sales and bring the firm back to growth? [Morningstar analyst] Damien Conover , who covers Pfizer, thinks that the answer to that question is yes. He sees a lot of candidates that are either

    Damien Conover found at 1:48

    replace those sales and bring the firm back to growth? [Morningstar analyst] Damien Conover , who covers Pfizer, thinks that the answer to that question is yes. He sees a lot of candidates that are either in
  9. Scale and Patent Protection Integral Parts of Lilly's Moat

    Video Reports

    Wed, 7 Nov 2012

    Damien Conover : I am Damien Conover , director of pharmaceutical research at Morningstar. I'm ..... Thanks, Dave, and thanks everyone for joining me. I'm Damien Conover , director of pharmaceutical research at Morningstar. Thank

    Damien Conover found at 0:00, 9:34

    Damien Conover : I am Damien Conover , director of pharmaceutical research at Morningstar. I'm pleased to be joined by Dave Ricks, head of Eli Lilly's Bio-Medicines group, the largest
    Conover: OK, great. Thanks, Dave, and thanks everyone for joining me. I'm Damien Conover , director of pharmaceutical research at Morningstar. Thank you.
  10. Big Pharma Dividends Alive and Well

    Video Reports

    Tue, 18 Sep 2012

    at is the pharmaceutical industry. I am here with Damien Conover , our director of pharmaceutical research, to take a closer look. Damien, thanks for joining me today. Damien Conover : Thanks for having me, Jeremy. Glaser: So, let's

    Damien Conover found at 0:12

    have been looking at is the pharmaceutical industry. I am here with Damien Conover , our director of pharmaceutical research, to take a closer look. Damien, thanks for joining me today. Damien Conover : Thanks for having me, Jeremy. Glaser: So, let's talk a little bit about some of the structural aspects of the pharmaceutical industry
« Prev123Next »
Content Partners